



**The Clatterbridge  
Cancer Centre**  
NHS Foundation Trust

Clatterbridge Road  
Bebington  
Wirral  
CH63 4JY

Tel: 0151 556 5000  
Web: [www.clatterbridgecc.nhs.uk](http://www.clatterbridgecc.nhs.uk)

Date: 17 June 2020

**Re: Freedom of Information Request**  
**Ref: 110- 2020**

Thank you for your email dated the 19<sup>th</sup> May 2020, requesting information regarding treatment figures.

The information that you require is as follows:

**Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:**

- 1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?**

**253 patients have been treated in the past 6 months.**

- 2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?**

**Locally advanced**

**Recurrent**

**Metastatic**

**Unresectable**

**Unknown - Unfortunately we are unable to provide this information as CCC only collects staging upon presentation to the Trust.**

3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?

**December 2019 – May 2020**

Carboplatin (only or in combination with 5-FU)	8
Cisplatin (only or in combination with 5-FU)	Exempt under S.40
Cetuximab with/without chemotherapy	Exempt under S.40
Cetuximab with radiotherapy	0
Pembrolizumab monotherapy	0
Pembrolizumab with chemotherapy	0
Nivolumab	16
Docetaxel (only or in combination with 5-FU)	0
Fluorouracil (5FU)	0
Radiotherapy only	144
Other	71

Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

**December 2019 – May 2020**

COMPARE	7
NICO	6
Javelin	Exempt under S.40

4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

**December 2019 – May 2020**

Aflibercept	0
Bevacizumab	0
Capecitabine	39
CAPIRI	12
CAPOX	167
Cetuximab not in combination with FOLFIRI or FOLFOX	13
Cetuximab in combination with FOLFIRI	12
Cetuximab in combination with FOLFOX	7
Irinotecan	25
FOLFIRI	76
FOLFOX	97
Oxaliplatin	0
Panitumumab not in combination with FOLFIRI or FOLFOX	Exempt under S.40
Panitumumab in combination with FOLFIRI	Exempt under S.40
Panitumumab in combination with FOLFOX	6
Nivolumab	0
Raltitrexed	0
Ramucirumab	0
Regorafenib	Exempt under S.40
Sorafenib	0
5FU only	36
Tegafur Uracil + 5FU	0

Trifluridine–tipiracil	18
XELOX	As above (CAPOX)
Other	97

5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:

**December 2019 – May 2020**

Sunitinib	8
Avelumab + Axitinib	13
Axitinib	Exempt under S.40
Cabozantinib	44
Everolimus	Exempt under S.40
Lenvantinib + Everolimus	0
Nivolumab	49
Nivolumab + Ipilimumab	Exempt under S.40
Pazopanib	8
Pembrolizumab + Axitinib	0
Sunitinib	As above (Sunitinib)
Temsirolimus	0
Tivozanib	15
Other	20

Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

**December 2019 – May 2020**

PRISM	9
RAMPART	8

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.